Gain-of-function mutations in KRAS are present in ∼25% of human lung adenocarcinomas and are truncal events, acquired early in disease development (Abbosh et al., 2017; Rakhit et al., 2017). This evidence concerns the gene KRAS and lung adenocarcinoma.